Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines

被引:28
|
作者
Perez, EA [1 ]
Buckwalter, CA [1 ]
机构
[1] Mayo Clin Jacksonville, Div Hematol Oncol, Jacksonville, FL 32224 USA
关键词
cell culture; breast; lung; etoposide; paclitaxel;
D O I
10.1007/s002800050765
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the effect of schedule on the interaction of etoposide with paclitaxel in vitro against the A549 human lung cancer cell line and the MDA-231 and MCF-7 human breast cancer cell lines. Methods: Exposure schedules that were 24-h concurrent, 24-h sequential, and sequential 24-h with a 24-h intervening drug-free period were quantitatively evaluated by the use of the median-effect principle and the combination index. The clonogenic assay was used to assess cytotoxicity, and calculations were done with computer software. Results: Concurrent exposures were less than additive in two of the three cell lines tested. Sequential 24-hour and sequential 24-h with an intervening 24-h drug-free period showed synergism at high effect levels in all three cell lines. Similar synergistic interactions were found when either agent was administered first. Conclusions: These results show a schedule-dependent cytotoxic interaction between etoposide and paclitaxel in the human lung and breast cancer cell lines evaluated, with optimal synergism occurring with sequential, but not with concurrent, treatment.
引用
收藏
页码:448 / 452
页数:5
相关论文
共 50 条
  • [31] Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines
    Klaassen, U
    Harstrick, A
    Schleucher, N
    Vanhoefer, U
    Schroder, J
    Wilke, H
    Seeber, S
    BRITISH JOURNAL OF CANCER, 1996, 74 (02) : 224 - 228
  • [32] Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma
    Hainsworth, JD
    Stroup, SL
    Greco, FA
    CANCER, 1996, 77 (12) : 2458 - 2463
  • [33] Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer
    Perez, EA
    Geoffroy, FJ
    Hillman, S
    Johnson, EA
    Farr, GH
    Tazelarr, HD
    Hatfield, AK
    Krook, JE
    Maillard, JA
    Levitt, R
    Marks, RS
    LUNG CANCER, 2004, 44 (03) : 347 - 353
  • [34] Cytotoxicity of liposomal paclitaxel in breast cancer cell line MCF-7
    Esfahani M.K.M.
    Alavi S.E.
    Movahedi F.
    Alavi F.
    Akbarzadeh A.
    Indian Journal of Clinical Biochemistry, 2013, 28 (4) : 358 - 360
  • [35] Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol™) in murine and human breast cancer cell lines
    Zaks-Zilberman, M
    Zaks, TZ
    Vogel, SN
    CYTOKINE, 2001, 15 (03) : 156 - 165
  • [36] Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I–II study
    C Tibaldi
    T Prochilo
    F Russo
    M C Pennucci
    A Del Freo
    F Innocenti
    A Fabbri
    A Falcone
    P F Conte
    E Baldini
    British Journal of Cancer, 2006, 94 : 1263 - 1266
  • [37] The association of increased lung resistance protein expression with acquired etoposide resistance in human H460 lung cancer cell lines
    Eunmyong Lee
    Soo-Jeong Lim
    Archives of Pharmacal Research, 2006, 29 : 1018 - 1023
  • [38] The association of increased lung resistance protein expression with acquired etoposide resistance in human H460 lung cancer cell lines
    Lee, Eunmyong
    Lim, Soo-Jeong
    ARCHIVES OF PHARMACAL RESEARCH, 2006, 29 (11) : 1018 - 1023
  • [39] Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines
    Janss, AJ
    Cnaan, A
    Zhao, HQ
    Shpilsky, A
    Levow, C
    Sutton, L
    Phillips, PC
    ANTI-CANCER DRUGS, 1998, 9 (07) : 641 - 652
  • [40] Human Lactoferrin Synergizes with Etoposide to Inhibit Lung Adenocarcinoma Cell Growth While Attenuating Etoposide-Mediated Cytotoxicity of Human Endothelial Cells
    Olszewska, Paulina
    Pazdrak, Barbara
    Kruzel, Marian L.
    BIOMEDICINES, 2022, 10 (10)